VTRS News & Events

Reports Q4 revenue $3.7B, consensus $3.53B. "2025 was a year of strong execution across our global business, and we enter 2026 from a position of strength," said Scott Smith, CEO, Viatris. "Today marks an important inflection point in Viatris' evolution. We have just completed our enterprise-wide strategic review to help make Viatris a more focused, efficient and future-ready organization. By realigning resources and prioritizing investments in the areas we believe will drive the greatest impact, we are positioning Viatris to deliver sustained revenue and earnings growth beginning in 2026. As we look ahead to our Investor Event on March 19, we are excited to share more about our strategy, our portfolio and how we intend to create lasting value for patients and shareholders."

Sees FY26 revenue $14.45B-$14.95B, consensus $14.37B. Sees FY26 adjusted EBITDA $4.15B-$4.45B. Sees FY26 free cash flow $1.95B-$2.35B. "Our strong performance for the fourth quarter and full year reflect our continued disciplined execution as we delivered on our 2025 financial commitments. We generated substantial cash for the year and prioritized capital return, with over $1 billion returned to shareholders," said Doretta Mistras, CFO, Viatris. "In 2026, we anticipate continued operational growth driven by our base business and net cost savings. We also expect to be in a strong financial position with significant cash available for deployment to deliver on our balanced capital allocation framework."

Viatris announced that the FDA has accepted for review the supplemental new drug application, or sNDA, for MR-141 for the treatment of presbyopia. The FDA has assigned a PDUFA goal date of October 17. Presbyopia is the age-related progressive loss of the ability to focus on close objects that results in blurred near vision and eye strain. The condition affects approximately 90% of adults in the U.S. over the age of 45.